Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Albuterol sulfate/fluticasone propionate - Teva Branded Pharmaceutical Industries

Next Previous
X
Search
Drug Profile

Albuterol sulfate/fluticasone propionate - Teva Branded Pharmaceutical Industries

Alternative Names: Fluticasone propionate/albuterol sulfate; Fp/ABS eMDPI; ICS-SABA; Salbutamol sulfate/fluticasone propionate - Teva Branded Pharmaceutical Industries; TEV-56248; TEV‘248

Latest Information Update: 23 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Bronchodilators; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Asthma
  • Phase I Respiratory tract disorders

Most Recent Events

  • 02 Apr 2024 Teva Pharmaceutical initiates enrolment in a phase I trial in Asthma (In children) in USA (Inhalation) (NCT06290102)
  • 01 Apr 2024 Launch Therapeutics and Teva Pharmaceutical enters into clinical collaboration for the clinical development of Albuterol sulfate/fluticasone propionate
  • 01 Apr 2024 Phase-III clinical trials in Asthma (Inhalation) prior to April 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top